Physician profile
Jorge M Davidenko
NPI 1215923990
$7,334.99
in general payments reported to CMS, 2019-2025
18 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,951 · 2020: $879 · 2021: $181 · 2022: $288 · 2023: $525 · 2024: $304 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,014.59 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,445.42 | 2019-2024 | Watchman Flx, Watchman Access System |
| Medtronic, INC. | $330.58 | 2021-2024 | Evera Mri Xt Dr Surescan, Azure Xt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $262.04 | 2022-2023 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $209.22 | 2020-2021 | |
| Medtronic Vascular, INC. | $201.16 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $177.30 | 2019-2023 | Brilinta |
| Abbott Laboratories | $158.56 | 2021-2025 | Mitraclip |
| Bayer Healthcare Pharmaceuticals INC. | $110.78 | 2019 | |
| Abiomed | $93.81 | 2024 | Impella |
| Amgen INC. | $72.50 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.70 | 2019 | |
| Baxter Healthcare | $59.24 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Vifor Pharma, INC. | $43.50 | 2021 | |
| Philips North America LLC | $33.78 | 2023 | |
| Scpharmaceuticals INC. | $23.89 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.70 | 2023 | Verquvo |
| Bardy Diagnostics, INC. | $18.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Davidenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.